The Environmental Determinants of Diabetes in the Young

Last updated

The Environmental Determinants of Diabetes in the Young is a longitudinal study examining the environmental causes of Type 1 diabetes (T1D), formerly known as juvenile diabetes. The study follows children at high genetic risk for T1D from birth to 15 years of age.

Contents

Although genetic markers for Type 1 Diabetes have been identified, genetic predisposition is not the only factor in development of the disease. An increasing body of evidence, including rising rates of T1D diagnosis and incomplete penetrance of the disease in genetically predisposed individuals, suggests that environment may play an equally important role. [1] TEDDY researchers hypothesize that a range of environmental factors have the ability to influence both the initial development of pancreatic beta-cell autoimmunity and the ultimate progression from autoimmunity to diabetes. [2]

TEDDY monitors participants for the presence of antibodies to insulin, GAD, IA2, and ZnT8 through regular testing. Study participants also provide a range of samples designed to give a comprehensive view of their exposure to environmental factors which could possibly trigger or protect against the development of autoimmunity and T1D. Samples collected for analysis include blood, nasal swabs, saliva, urine, stool, toenails, and drinking water. Additionally, researchers collect diet records and interview subjects and their caretakers to assess the subjects’ stress levels, determine the impact of major life changes, and identify additional environmental factors such as illnesses, immunizations, allergies, and pets.

TEDDY is funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Child Health and Human Development (NICHD), National Institute of Environmental Health Sciences (NIEHS), Juvenile Diabetes Research Foundation (JDRF), and the Centers for Disease Control and Prevention. [3]

History of the TEDDY Study

Timeline of Key Events in the History of the TEDDY Study. Timeline of key events in the TEDDY study.png
Timeline of Key Events in the History of the TEDDY Study.

Establishment of the TEDDY Consortium

In 2002, the TEDDY consortium was created. This consortium is made up of six clinical centers, three based in the United States (located in Colorado, Georgia, and Washington State) and three in Europe (in Germany, Sweden, and Finland). [4]

A single Data Coordinating Center is also included in the TEDDY consortium. [5] The DCC, located in Florida, is responsible for the comparison and synthesis of information from each of the clinical centers.

Subject Recruitment

Recruitment for the TEDDY study began in 2004 and was completed in 2010. [6] Potential TEDDY subjects were identified at birth by genetic screening of the HLA-DR/DQ loci, which are considered to be highly important in determining whether an individual will develop Type 1 Diabetes. [7] Parents of newborns with HLA DR/DQ genotypes associated with a high risk for T1D were approached for enrollment in the study. [6]

TEDDY researchers screened a total of 421,047 newborns, with 26,239 eligible for the study. Slightly over 22% of newborns with a first degree relative with T1D were eligible for enrollment in the study. Only about 5% of newborns from the general population (no first degree relative with T1D) were eligible. [6]

Major Findings

Several publications have suggested a link between participation in the TEDDY study and fewer complications at T1D diagnosis. In 2011, one report found that children in TEDDY are less likely to experience diabetic ketoacidosis (DKA) at the time of diagnosis. [8] DKA is a serious complication which is particularly common in children under five years of age and can lead to cerebral edema, coma, and death. [9]

A 2013 publication also stated that children who develop T1D while enrolled in TEDDY are diagnosed sooner after the onset of the disease than those not in the study. Among children who are not enrolled in a research study, 99% are symptomatic at the time of T1D diagnosis. [10] However, of the 100 children in TEDDY who had been diagnosed with T1D at the time of publication, only 64% were symptomatic. Researchers believe that this difference can be attributed to the close monitoring of TEDDY subjects through methods such as regular autoantibody testing and oral glucose tolerance tests. [3] Earlier diagnosis of T1D is associated with fewer long-term complications and better preservation of function in remaining pancreatic β-cells. [11]

Related Research Articles

<span class="mw-page-title-main">Diabetic ketoacidosis</span> Medical condition

Diabetic ketoacidosis (DKA) is a potentially life-threatening complication of diabetes mellitus. Signs and symptoms may include vomiting, abdominal pain, deep gasping breathing, increased urination, weakness, confusion and occasionally loss of consciousness. A person's breath may develop a specific "fruity" smell. The onset of symptoms is usually rapid. People without a previous diagnosis of diabetes may develop DKA as the first obvious symptom.

<span class="mw-page-title-main">Diabetic retinopathy</span> Medical condition

Diabetic retinopathy, is a medical condition in which damage occurs to the retina due to diabetes mellitus. It is a leading cause of blindness in developed countries.

<span class="mw-page-title-main">Diabetic coma</span> Medical condition

Diabetic coma is a life-threatening but reversible form of coma found in people with diabetes mellitus.

<span class="mw-page-title-main">Kussmaul breathing</span> Hyperventilation associated with metabolic acidosis

Kussmaul breathing is a deep and labored breathing pattern often associated with severe metabolic acidosis, particularly diabetic ketoacidosis (DKA) but also kidney failure. It is a form of hyperventilation, which is any breathing pattern that reduces carbon dioxide in the blood due to increased rate or depth of respiration.

Maturity-onset diabetes of the young (MODY) refers to any of several hereditary forms of diabetes mellitus caused by mutations in an autosomal dominant gene disrupting insulin production. Along with neonatal diabetes, MODY is a form of the conditions known as monogenic diabetes. While the more common types of diabetes involve more complex combinations of causes involving multiple genes and environmental factors, each forms of MODY are caused by changes to a single gene (monogenic). GCK-MODY and HNF1A-MODY are the most common forms.

<span class="mw-page-title-main">Type 1 diabetes</span> Form of diabetes mellitus

Type 1 diabetes (T1D), formerly known as juvenile diabetes, is an autoimmune disease that originates when cells that make insulin are destroyed by the immune system. Insulin is a hormone required for the cells to use blood sugar for energy and it helps regulate glucose levels in the bloodstream. Before treatment this results in high blood sugar levels in the body. The common symptoms of this elevated blood sugar are frequent urination, increased thirst, increased hunger, weight loss, and other serious complications. Additional symptoms may include blurry vision, tiredness, and slow wound healing. Symptoms typically develop over a short period of time, often a matter of weeks if not months.

The Burlo Garofolo Pediatric Institute is a children's hospital located in Trieste, Italy.

Slowly evolving immune-mediated diabetes, or latent autoimmune diabetes in adults (LADA), is a form of diabetes that exhibits clinical features similar to both type 1 diabetes (T1D) and type 2 diabetes (T2D), and is sometimes referred to as type 1.5 diabetes. It is an autoimmune form of diabetes, similar to T1D, but patients with LADA often show insulin resistance, similar to T2D, and share some risk factors for the disease with T2D. Studies have shown that LADA patients have certain types of antibodies against the insulin-producing cells, and that these cells stop producing insulin more slowly than in T1D patients.

Hyperosmolar hyperglycemic state (HHS), also known as hyperosmolar non-ketotic state (HONK), is a complication of diabetes mellitus in which high blood sugar results in high osmolarity without significant ketoacidosis. Symptoms include signs of dehydration, weakness, leg cramps, vision problems, and an altered level of consciousness. Onset is typically over days to weeks. Complications may include seizures, disseminated intravascular coagulopathy, mesenteric artery occlusion, or rhabdomyolysis.

Teplizumab, sold under the brand name Tzield, is a humanized anti-CD3 monoclonal antibody that is the first approved treatment indicated to delay the onset of stage 3 type 1 diabetes (T1D) in people with stage 2 T1D.

Biobreeding rat, also known as the BB or BBDP rat, is an inbred laboratory rat strain that spontaneously develops autoimmune Type 1 Diabetes. Like the NOD mice, BB rats are used as an animal model for Type 1 diabetes. The strain re-capitulates many of the features of human type 1 diabetes, and has contributed greatly to the research of T1D pathogenesis.

Anti-transglutaminase antibodies (ATA) are autoantibodies against the transglutaminase protein. Antibodies serve an important role in the immune system by detecting cells and substances that the rest of the immune system then eliminates. These cells and substances can be foreign and also can be produced by the body. Antibodies against the body's own products are called autoantibodies. Autoantibodies can sometimes errantly be directed against healthy portions of the organism, causing autoimmune diseases.

<span class="mw-page-title-main">Neonatal diabetes</span> Medical condition

Neonatal diabetes mellitus (NDM) is a disease that affects an infant and their body's ability to produce or use insulin.NDM is a kind of diabetes that is monogenic and arises in the first 6 months of life. Infants do not produce enough insulin, leading to an increase in glucose accumulation. It is a rare disease, occurring in only one in 100,000 to 500,000 live births. NDM can be mistaken for the much more common type 1 diabetes, but type 1 diabetes usually occurs later than the first 6 months of life. There are two types of NDM: permanent neonatal diabetes mellitus (PNDM), a lifelong condition, and transient neonatal diabetes mellitus (TNDM), a form of diabetes that disappears during the infant stage but may reappear later in life.

Complications of diabetes are secondary diseases that are a result of elevated blood glucose levels that occur in diabetic patients. These complications can be divided into two types: acute and chronic. Acute complications are complications that develop rapidly and can be exemplified as diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar state (HHS), lactic acidosis (LA), and hypoglycemia. Chronic complications develop over time and are generally classified in two categories: microvascular and macrovascular. Microvascular complications include neuropathy, nephropathy, and retinopathy; while cardiovascular disease, stroke, and peripheral vascular disease are included in the macrovascular complications.

<span class="mw-page-title-main">Diabetes in dogs</span>

Diabetes mellitus is a disease in which the beta cells of the endocrine pancreas either stop producing insulin or can no longer produce it in enough quantity for the body's needs. The disease can affect humans as well as animals such as dogs.

The following outline is provided as an overview of and topical guide to diabetes mellitus :

Ketosis-prone diabetes (KPD) is an intermediate form of diabetes that has some characteristics of type 1 and some of type 2 diabetes. Type 1 diabetes involves autoimmune destruction of pancreatic beta cells which create insulin. This occurs earlier in a person's life, leading to patients being insulin dependent, and the lack of natural insulin makes patients prone to a condition called diabetic ketoacidosis (DKA). Type 2 diabetes is different in that it is usually caused by insulin resistance in the body in older patients leading to beta cell burnout over time, and is not prone to DKA. KPD is a condition that involves DKA like type 1, but occurs later in life and can regain beta cell function like type 2 diabetes. However, it is distinct from latent autoimmune diabetes of adults (LADA), a form of type 1 sometimes referred to as type 1.5 that does not occur with DKA. There are also distinctions to be made between KPD and LADA as patients who exhibit KPD symptoms can regain beta cell function similar to type 2 diabetics whereas LADA will not exhibit this reclamation of beta cell function.

<span class="mw-page-title-main">Diabetes</span> Group of endocrine diseases characterized by high blood sugar levels

Diabetes mellitus, often known simply as diabetes, is a group of common endocrine diseases characterized by sustained high blood sugar levels. Diabetes is due to either the pancreas not producing enough insulin, or the cells of the body becoming unresponsive to the hormone's effects. Classic symptoms include thirst, polyuria, weight loss, and blurred vision. If left untreated, the disease can lead to various health complications, including disorders of the cardiovascular system, eye, kidney, and nerves. Untreated or poorly treated diabetes accounts for approximately 1.5 million deaths every year.

<span class="mw-page-title-main">ENDIA</span>

The Environmental Determinants of Islet Autoimmunity (ENDIA) Study is an Australian prospective pregnancy cohort study investigating the environmental triggers responsible for the autoimmune process that leads to type 1 diabetes. The study is led by Professor Jennifer Couper from the University of Adelaide in South Australia with collaborators from the Walter and Eliza Hall Institute, Royal Melbourne Hospital, Monash University and Monash Medical Centre in Victoria, the University of NSW and the Children's Hospital at Westmead, the Royal Hospital for Women and St. George's Hospital in NSW, the University of Queensland and Mater Health Services in Queensland, and the University of Western Australia and Princess Margaret Hospital for Children in Western Australia.

<span class="mw-page-title-main">Catherine Cowie</span> American epidemiologist

Catherine Christine Cowie is an American epidemiologist. She is a program director and senior advisor at the National Institute of Diabetes and Digestive and Kidney Diseases.

References

  1. ↑ TEDDY Study Group. The environmental determinants of diabetes in the young (TEDDY) Study. Immunology of Diabetes V. 2008; 1150: 1-13.
  2. ↑ NIDDK. TEDDY Protocol. NIDDK Repository. https://www.niddkrepository.org/static/studies/teddy/teddy_protocol.pdf. Accessed December 18, 2013.
  3. 1 2 Larsson, H.E., Vehik, K., Gesualdo, P., et al. Children followed in the TEDDY study are diagnosed with Type 1 diabetes at an early stage of disease. Pediatric Diabetes. 2013; 10: 1-9.
  4. ↑ TEDDY Study Group. What is TEDDY? TEDDY. http://teddy.epi.usf.edu/research/. Accessed December 13, 2013.
  5. ↑ National Institute of Health. The TEDDY Consortium. NIDDK. http://archives.niddk.nih.gov/patient/TEDDY/TEDDY.aspx#2. Accessed December 13, 2013.
  6. 1 2 3 Hagopian, W.A., Erlick, H., Lernmark, A. et al. The Environmental Determinants of Diabetes in the Young (TEDDY): genetic criteria and international risk screening of 421 000 infants. Pediatric Diabetes. 2011; 12: 733-743.
  7. ↑ Peng, H. & Hagopian, W. Environmental factors in the development of Type 1 diabetes. Reviews in Endocrine and Metabolic Disorders. 2006; 7: 149-162.
  8. ↑ Larsson, H.E., Vehik, K., Bell, R., et al. Reduced prevalence of diabetic ketoacidosis at diagnosis of Type 1 diabetes in young children participating in longitudinal follow-up. Diabetes Care. 2011; 34: 2347-2352.
  9. ↑ Wolfsdorf, J., Glaser, N., Sperling, M.A. Diabetic ketoacidosis in infants, children, and adolescents: a consensus statement from the American Diabetes Association. Diabetes Care. 2006; 29:1150-1159.
  10. ↑ Quinn, M., Fleischman, A., Rosner, B., et al. Characteristics at diagnosis of Type 1 diabetes in children younger than 6 years. Journal of Pediatrics. 2006; 148: 366-371.
  11. ↑ Ludvigsson, J. Immune intervention at diagnosis- should we treat children to preserve beta-cell function? Pediatric Diabetes. 2007; 8: 34-39.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.